<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144246</url>
  </required_header>
  <id_info>
    <org_study_id>819889</org_study_id>
    <nct_id>NCT02144246</nct_id>
  </id_info>
  <brief_title>Contraceptive Hormones and Women With Cystic Fibrosis</brief_title>
  <official_title>Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective Our primary objective in this study is to evaluate satisfaction of hormonal
      contraception in this sample of women and to evaluate the impact that this hormonal
      contraceptive has on cystic fibrosis (CF) disease in women with regular menstrual cycles
      accompanied by cyclic exacerbations.

      We hypothesize:

      1a) women with CF who perceive an overall benefit of hormonal contraception will be more
      satisfied than women with CF who do not perceive a benefit,

      1b) women with CF who have cyclic exacerbations will have decreased Pseudomonas aeruginosa
      mucoidy conversion while using hormonal contraception,

      1c) women with CF who have cyclic exacerbations will have improved patient-reported quality
      of life indices while on hormonal contraception, and

      1d) women with CF who have cyclic exacerbations will have improvement in pulmonary function
      tests while on hormonal contraception.

      Secondary Objective We plan to secondarily evaluate the cervical mucus of women with CF at
      the time of ovulation and compare it to that of healthy controls.

      We hypothesize that women with CF have ovulatory cervical mucus similar to healthy peers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction with contraception</measure>
    <time_frame>18 months</time_frame>
    <description>Satisfaction overall</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>18 months</time_frame>
    <description>Pseudomonas mucoidy conversion Quality of life Pulmonary function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with contraception</measure>
    <time_frame>18 months</time_frame>
    <description>Satisfaction overall measured by a visual analog scale 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cervical Mucus</measure>
    <time_frame>3 months</time_frame>
    <description>Cervical mucus of CF patients relative to healthy controls</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception</condition>
  <arm_group>
    <arm_group_label>Pre-intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will act as their own controls. Will have no hormones for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-hormonal period</intervention_name>
    <arm_group_label>Pre-intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg</intervention_name>
    <arm_group_label>Post-intervention</arm_group_label>
    <other_name>Mononessa</other_name>
    <other_name>Sprintec</other_name>
    <other_name>Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female, reproductive age (18-40), cyclic CF exacerbations, regular menstrual cycles

        Exclusion Criteria:

          -  pregnant, desires pregnancy, contra-indication to hormonal contraception, currently
             using hormonal contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Courtney Schreiber</investigator_full_name>
    <investigator_title>Family Planning Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate</mesh_term>
    <mesh_term>Norgestrel</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

